The Correlations Of Serum HBV DNA, Hbsag And HBeAg In Patients With Chronic Hepatitis B

Backgroud Chronic hepatitis B is one of the major infectious diseases，HBV infectioncan significantly increase the incidence of the liver failure and liver cirrhosis andHepaocellular carcinoma (HCC) and cause a great harmness to human health. HepatitisB surface antigen (HBsAg) testing as the preferred method of screening and alarge-scale epidemiology. Serum HBV DNA tested as the direct method to evaluationHBV replication level are widely used. Chronic HBV infection become divided intofour stages: immune tolerance period, immune clearance period, the activity or low (not)copy period and then active period. Later in its natural history, especially the antiviraltreatment process, HBV DNA level down or undetectable, It is difficult to estimate theantiviral treatment effect. Serum HBV DNA was tested by fluorescence quantitativepolymerase chain reaction (FQ-PCR), and HBsAg and HBeAg were detected bychemiluminesent microparticle immunoassay (CMIA）in the study. To investigate thecorrelations of serum HBV DNA and HBsAg and HBeAg levels in patients withchronic hepatitis B.At the same time, HBV markers also were tested by Enzyme leagueimmune (ELISA). To compare the two methods, this paper discussed the question waswhether the quantitative detection was any better than qualitative tests in theevaluation of the antiviral treatment effect.Objective To investigate the correlations of serum HBV DNA and HBsAg andHBeAg levels in patients with chronic hepatitis B.Methods951patients with CHB were enrolled. Serum HBV DNA was tested by FQ-PCR, and HBsAg and HBeAg were detected by CMIA.1190patients with CHBalso were enrolled to test HBV markers by ELISA. To compare the the antiviraltreatment effect of two methods in treating CHB。Results53.6%patients were HBV DNA positive in951patients with CHB，thepercentage of the patients who were HBsAg, HBeAg and HBcAb positive was40.62%(396/951), the HBsAg, HBeAb and HBcAb positive was45.85%(447/951), the HBsAgand HBcAb positive was4.41%(43/951), others was9.12%(65/951).The serumHBsAg and HBeAg concentrations were positively correlated with serum HBV DNAlevels (rS=0.45and rs=0.49, respectively, p<0.05); The serum HBV DNA weredivided into3groups(eg.＜3lg copies/ml,3to7lg copies/ml and≥7lgcopies/ml)．There was an significant differences in serum HBsAg and HBeAg levelsamong the3groups （p<0.05); There was also an significant differences in serum HBVDNA levels among different serum HBsAg levels (eg.＜1000IU/ml,1000～10000IU/ml and≥10000IU/ml, p <0.05).1190patients were tested HBV markers by ELISAand the percentage of the patients who were HBsAg, HBeAg and HBcAb positive was41.09%(489/1190), the HBsAg, HBeAb and HBcAb positive was28.66%(341/1190),the HBsAg and HBcAb positive was30.35%(360/1190). the quantitative detection wasbetter than qualitative tests in the evaluation of the antiviral treatment effect (p <0.05).Conclusion Serum HBsAg concentration is related to serum HBV DNA levels inpatients with hepatitis B, but it is not feasible in most cases to use HBsAg concentrationfor monitoring their serum HBV levels. The quantitative detection was better thanqualitative tests in the evaluation of the antiviral treatment effect.